Montelukast

Drug Profile

Montelukast

Alternative Names: KIPRES; L-706631; MK-0476; MK-476; Montegen; Montelukast sodium; Romilast; Singulair

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Developer Banyu; CHA University; Kyorin Pharmaceutical; Merck & Co; Merck Sharp & Dohme; Sun Pharmaceutical Industries
  • Class Acetates; Anti-inflammatories; Antiasthmatics; Antidementias; Bronchodilators; Neuroprotectants; Nootropics; Quinolines; Small molecules
  • Mechanism of Action Leukotriene D4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic rhinitis; Asthma; Exercise-induced asthma; Perennial allergic rhinitis; Seasonal allergic rhinitis
  • No development reported Bronchitis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Allergic-rhinitis(In children) in South Korea (PO, Tablet)
  • 15 Mar 2016 Biomarkers information updated
  • 11 Dec 2015 Launched for Allergic rhinitis in Japan (KIPRES® OD tablets 10mg)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top